ImExHS Limited
ASX: IME
Expanding radiology platform adoption and solid contract wins.
(Source: TradingView) 3-Month Performance Profile of IME on a DTF compared to S&P/ASX 200 (XJO).
Aquila continued to gain meaningful commercial traction in FY25, with the next-generation radiology platform signing new multi-year contracts, including Clínica del Occidente and Hospital Moncaleano. The co
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
